Advertisement

Der Internist pp 179-192 | Cite as

Pharmakokinetische Grundlagen der Teratogenität von Arzneimitteln

Zusammenfassung

Aus der Darstellung wird ersichtlich, daß pharmakokinetische Parameter für die Teratogenität eines Arzneimittels — neben seiner Struktur -von ausschlaggebender Bedeutung sind. Zu diesen Aussagen führte häufig der Tierversuch, so daß Speziesunterschiede im Hinblick auf Teratogenität und Pharmakokinetik berücksichtigt werden mußten. Wie sich die Kenntnisse um die Teratogenität eines Arzneimittels mehren, geht aus der Erörterung neuer experimenteller und klinischer Befunde in bezug auf das Antiepileptikum Valproinsäure hervor, wobei auf mögliche Konsequenzen für die Praxis aufgrund der Ergebnisse aufmerksam gemacht wird. Zu anderen teratogenen Arzneimitteln wie Thalidomid, Phenytoin sowie Retinoide finden sich ebenfalls Hinweise, die zum Verständnis dieser Eigenschaft beitragen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Beck F (1976) Comparative placental morphology and function. Environ Health Perspect 18:5–12PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Brown NA, Fabro S (1983) The value of animal teratogenicity testing for predicting human risk. Clin Obstet Gynecol 26:467–477PubMedCrossRefGoogle Scholar
  3. 3.
    Brown NA, Coakley ME, Clarke DO (1987) Structure-tera-togenicity relationships of valproic acid congeners in whole-embryo culture. In: Welsch F (Hrsg) Approaches to elucidate mechanisms in teratogenesis. Hemisphere Publishing Corporation, Washington, pp 17–31Google Scholar
  4. 4.
    Chodera A, Feller K (1978) Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol 16:357–360Google Scholar
  5. 5.
    Clarke DO, Brown NA (1987) Altered cholesterol levels and metabolic response of rat conceptuses exposed to valproic acid (VPA) in vitro. Teratology 35:17AGoogle Scholar
  6. 6.
    Creech Kraft J, Kochhar DM, Scott WJ, Nau H (1987) Low teratogenicity of 13-cis-retinoic acid (Isotretinoin) in the mouse corresponds to low embryo concentrations during organogenesis: comparison to the all-trans isomer. Toxicol Appl Pharmacol 87:474–482CrossRefGoogle Scholar
  7. 7.
    Dencker L (1987) Transfer of drugs to the embryo and fetus after placentation. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol I, Interspecies comparison and maternal/embryonic fetal drug transfer. CRC Press, Inc. Boca Raton, pp 55–70Google Scholar
  8. 8.
    Di Carlo FJ, Bickart P, Auer CM (1986) Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. II. Application to teratogenicity and other toxic effects caused by aliphatic acids. Drug Metabol Rev 17:187–220CrossRefGoogle Scholar
  9. 9.
    Garbis-Berkvens JM, Peters PWJ (1987) Comparative morphology and physiology of embryonic and fetal membranes. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol I. Interspecies comparison and maternal embryonic fetal drug transfer. CRC Press, Inc. Boca Raton, pp 13–44Google Scholar
  10. 10.
    Gordon GB, Spielberg SP, Blake DA, Balasubramanian V (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 78:2545–2548PubMedCrossRefGoogle Scholar
  11. 11.
    Happle R, Traupe H, Bounameaux, Fisch T (1984) Terato-gene Wirkung von Etretinat beim Menschen. Dtsch Med Wochenschr 109:1476–1480PubMedCrossRefGoogle Scholar
  12. 12.
    Helm F-Ch, Frankus E, Friderichs E, Graudums I, Flohé L (1981) Comparative teratological investigation of compounds structurally and pharmacologically related to Thalidomide. Arzneimittelforschung 31:941–949PubMedGoogle Scholar
  13. 13.
    Hendrickx AG, Binkerd PE, Rowland JM (1983) Developmental toxicity and nonhuman primates. In: Kalter H (Hrsg) Issues and reviews in teratology, Vol. 1.. Plenum Publishing Corporation, New York, pp 149–180CrossRefGoogle Scholar
  14. 14.
    Hiilesmaa VK, Teramo K, Granström M-L, Bardy AH (1983) Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br Med J 287:577–579CrossRefGoogle Scholar
  15. 15.
    Finnell R (1987) Gene-teratogen interactions: an approach to understanding the metabolic basis of birth defects. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol 2. Experimental aspects in vivo and in vitro. CRC Press, Inc. Boca Raton, pp 97–109Google Scholar
  16. 16.
    Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skpper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother 50:219–245Google Scholar
  17. 17.
    Jäger-Roman E, Deichl A, Jakob S, Hartmann A-M, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004PubMedCrossRefGoogle Scholar
  18. 18.
    Janz D (1984) Schwangerschaft und Kindesentwicklung bei Epilepsie. Geburtshilfe Frauenheilkde 44:428–434CrossRefGoogle Scholar
  19. 19.
    Kalin JR, Wells MJ, Hill DL (1982) Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses. Drug Metabol Disp 10:391–398Google Scholar
  20. 20.
    Kao J, Brown NA, Schmid B, Goulding EH, Fabro S (1981) Teratogenicity of valproic acid: in vivo and in vitro investigations. Teratogenesis Carcinog Mutagen 1:367–382CrossRefGoogle Scholar
  21. 21.
    Kietzmann H, Schwarze I, Grote W, Ravens U, Jänig U, Harms D (1986) Embryonale Fehlbildung bei Etretinat-Therapie der Mutter wegen Morbus Darier. Dtsch Med Wochenschr 111:60–62PubMedCrossRefGoogle Scholar
  22. 22.
    Kochen W, Schneider A, Ritz A (1983) Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr 141:30–35PubMedCrossRefGoogle Scholar
  23. 23.
    Kochhar DM, Kraft J, Nau H (1987) Teratogenicity and disposition of various retinoids in vivo and in vitro. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol II. Experimental aspects in vivo and in vitro. CRC Press Inc., Boca Raton, pp 173–186Google Scholar
  24. 24.
    Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW, Lott IT, Richard JM, Sun SS (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841PubMedCrossRefGoogle Scholar
  25. 25.
    Laurence KM, James N, Miller MH, Tennant GB, Campbell H (1981) Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J 282:1509–1511CrossRefGoogle Scholar
  26. 26.
    Lewandowski C, Klug S, Nau H, Neubert D (1986) Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentrations and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. Arch Toxicol 58:239–242PubMedCrossRefGoogle Scholar
  27. 27.
    Lindhout D, Meinardi H (1984) Spina bifida and in-utero exposure to valproate. Lancet II: 396CrossRefGoogle Scholar
  28. 28.
    Lindhout D, Schmidt D (1986) In utero exposure to valproate and neural tube defects. Lancet 1:1392–1393PubMedCrossRefGoogle Scholar
  29. 29.
    Löscher W, Nau H, Marescaux C, Vergnes M (1984) Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 99:211–218PubMedCrossRefGoogle Scholar
  30. 30.
    Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24:427–435PubMedCrossRefGoogle Scholar
  31. 31.
    Löscher W (1987) Neurophysiologische und neurochemi-sche Grundlagen der Wirkung von Antiepileptika. In: Heinrich K, Peter UH, Neundörfer B (Hrsg) Fortschritte der Neurologie. Psychiatric, Thieme, Stuttgart, S 141–174Google Scholar
  32. 32.
    Luck W, Nau H, Hansen R, Steldinger R (1985) Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther 8:384–395PubMedGoogle Scholar
  33. 33.
    Manchester D, Jacoby E (1984) Decreased placental mono-oxygenäse activities associated with birth defects. Teratology 30:31–37PubMedCrossRefGoogle Scholar
  34. 34.
    Massarella J, Vane F, Buggé C, Rodriguez L, Cunningham WJ, Franz T, Colburn W (1985) Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 37:439–446PubMedCrossRefGoogle Scholar
  35. 35.
    Mast TJ, Cukierski MA, Nau H, Hendrickx AG (1986) Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology 39:111–119PubMedCrossRefGoogle Scholar
  36. 36.
    Mast TJ, Nau H, Wittfoht W, Hendrickx AG (1987) Teratogenicity and pharmacokinetics of valproic acid in the rhesus monkey. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol I. Interspecies comparison and maternal embryonic fetal drug transfer. CRC Press, Inc. Boca Raton, pp 131–148Google Scholar
  37. 37.
    Nau H, Neubert D (1978) Development of drug metabolizing monooxygenase systems in various mammalian species including man: its significance for transplacental toxicity. In: Neubert D, Merker H-J, Nau H, Langman J (Hrsg) Role of pharmacokinetics in prenatal and perinatal toxicology. Thieme, Stuttgart, S 13–44Google Scholar
  38. 38.
    Nau H, Gansau C (1981) Development of cytochrome P-450-dependent drug metabolizing enzyme activities in mouse and human tissues in vitro. In: Neubert D, Merker H-J (Hrsg) Culture techniques. Walter de Gruyter, Berlin, pp 495–507Google Scholar
  39. 39.
    Nau H, Bass R (1981) Transfer of 2,3,7,8-tetrachlorodi-benzo-p-dioxin (TCDD) to the mouse embryo and fetus. Toxicology 20:299–308PubMedCrossRefGoogle Scholar
  40. 40.
    Nau H, Rating D, Koch S, Häuser I, Helge H (1981) Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219:768–777PubMedGoogle Scholar
  41. 41.
    Nau H, Wittfoht W, Schäfer H, Jakobs C, Rating D, Helge H (1981) Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography — mass spectrometry using selected ion monitoring. J Chromatogr 226:69–78PubMedCrossRefGoogle Scholar
  42. 42.
    Nau H, Zierer R, Spielmann H, Neubert D, Gansau C (1981) A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 29:2803–2814PubMedCrossRefGoogle Scholar
  43. 43.
    Nau H, Helge H, Luck W (1984) Valproic acid in perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 104:627–634PubMedCrossRefGoogle Scholar
  44. 44.
    Nau H (1985) Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243–250PubMedCrossRefGoogle Scholar
  45. 45.
    Nau H (1985) Clinical pharmacokinetics in pregnancy and perinatology. I. Placental transfer and fetal side effects of local anaesthetic agents. Dev Pharmacol Ther 8:149–181PubMedGoogle Scholar
  46. 46.
    Nau H (1986) Species differences in pharmacokinetics and drug teratogenesis. Environ Health Perspect 70:113–129PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Nau H (1986) Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metaboites assayed is implicated as teratogen. Fundan Appl Toxicol 6:662–668CrossRefGoogle Scholar
  48. 48.
    Nau H (1986) Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 33:21–27PubMedCrossRefGoogle Scholar
  49. 49.
    Nau H, Baß R, Neubert D (1986) Transfer of 2,3,7,8-te-trachlorodibenzo-p-dioxin (TCDD) via placenta and milk, and postnatal toxicity in the mouse. Arch Toxicol 59:36–40PubMedCrossRefGoogle Scholar
  50. 50.
    Nau H, Löscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6:669–676PubMedCrossRefGoogle Scholar
  51. 51.
    Nau H, Krauer B (1986) Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations. J Clin Pharmacol 26:215–221PubMedCrossRefGoogle Scholar
  52. 52.
    Nau H, Scott WJ (1986) Weak acids may act as teratogens by accumulating in the masic milieu of the early mammalian embryo. Nature 323:276–278PubMedCrossRefGoogle Scholar
  53. 53.
    Nau H (1987) Valproinsäure — Serumkonzentrationen bei Monotherapie mit Einmal-, Zweimal- und Mehrfachgabe pro Tag. Nervenarzt 58:459Google Scholar
  54. 54.
    Nau H, Hendrickx AG (1987) Valproic acid teratogenesis. ISI Atlas of Science: Pharmacology 1:52–56Google Scholar
  55. 55.
    Nau H, Mirkin BL (1987) Fetal and maternal clinical pharmacokinetics. In: Avery’s drug treatment principles and practice of clinical pharmacology and therapeutics., 3rd Ed. ADIS Press, Auckland, pp 79–117Google Scholar
  56. 56.
    Nau H, Scott WJ (1987) Teratogenicity of valproic acid and related substances in the mouse: drug accumulation and pHi in the embryo during organogenesis and structure-activity considerations. Arch Toxicol Suppl 11:128–139PubMedGoogle Scholar
  57. 57.
    Neubert D, Barrach HJ, Merker H-J (1980) Drug-induced damage to the embryo or fetus. In: Grundmann E (Hrsg) Current topics in pathology, Vol 69. Springer, Berlin Heidelberg New York, pp 242–331Google Scholar
  58. 58.
    Neubert D, Chahoud I (1985) Significance of species and strain differences in pre- and perinatal toxicology. Acta Histochem [Suppl] 31:23–35Google Scholar
  59. 59.
    Neubert D, Chahoud I, Platzek T, Meister R (1987) Principles and problems in assessing prenatal toxicity. Arch Toxicol 60:238–245PubMedCrossRefGoogle Scholar
  60. 60.
    Paravicini U, Stöckel K, MacNamara PJ, Hänni R, Buss-linger A (1981) On metabolism and pharmacokinetics of aromatic retinoid. Ann NY Acad Sci 359:54–67PubMedCrossRefGoogle Scholar
  61. 61.
    Reiners J, Zierer R, Spielmann H, Nau H (1986) Teratogenicity of steady-state infusion of etretinate (Tigason) throughout organogenesis in the mouse. Teratology 34:420AGoogle Scholar
  62. 62.
    Robert E, Guibaud P (1982) Maternal volproic acid and congenital neural tube defects. Lancet 11:937CrossRefGoogle Scholar
  63. 63.
    Schardein JL, Schwetz BA, Kenel MF (1985) Species sensitivities and prediction of tetratogenic potential. Environm Health Persp 61:55–67Google Scholar
  64. 64.
    Schmidt D (1984) Behandlung der Epilepsien, 2. Aufl. Thieme, StuttgartGoogle Scholar
  65. 65.
    Schumacher HJ (1975) Chemical structure and teratogenic properties. In: Shepard TH, Miller JR, Marais M (Hrsg) Methods for detection of environmental agents that produce congenital malformations. Elsevier, Amsterdam, pp 65–77Google Scholar
  66. 66.
    Smith, Clark (1987) Pharmacokinetics and toxicity testing: basic principles and pitfalls. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol I. Interspecies comparison and maternal embryonic fetal drug transfer. CRC Press, Inc. Boca Raton, pp 107–122Google Scholar
  67. 67.
    Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW (1981) Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 56:911–918PubMedCrossRefGoogle Scholar
  68. 68.
    Spielberg S (1987) Phenytoin-induced birth defects: the role of pharmacogenetic differences in areneoxide detoxification. In: Nau H, Scott WJ (Hrsg) Pharmacokinetics in teratogenesis, Vol I. Interspecies transfer and maternal/embryonic fetal drug transfer. CRC Press, Inc. Boca Raton, pp 225–232Google Scholar
  69. 69.
    Stahlmann R, Neubert D (1987) Welche Medikamente sind erlaubt, welche sollte man meiden, welche sind kontraindiziert? Gynäkologe 22:129–136Google Scholar
  70. 70.
    Stefan H, Burr W, Fröscher W (1986) Valproinsäure-Serumkonzentrationen bei Monotherapie mit Einmal-, Zweimal- und Mehrfachgabe pro Tag. Nervenarzt 57:640–648PubMedGoogle Scholar
  71. 71.
    Trotz M, Wegner C, Nau H (1987) Valproic-acid-induced neural tube defects: reduction by folinic acid in the mouse. Life Sci 41:103–110PubMedCrossRefGoogle Scholar
  72. 72.
    Tuchmann-Duplessis H (1984) Drugs and other xenobiotics as teratogens. Pharmacol Ther 26:273–344PubMedCrossRefGoogle Scholar
  73. 73.
    Whittle BA (1976) Pre-clinical, teratological studies on sodium valproate and other anticonvulsants. In: Legg NJ (Hrsg) Clinical and pharmacological aspects of sodium valproate (epilim) in the treatment of epilepsy. MCS Consultants, Tunbridge Wells, pp 105–110Google Scholar
  74. 74.
    Wilson JG, Scott WJ, Ritter EJ, Fradkin R (1979) Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology 19:71–80PubMedCrossRefGoogle Scholar
  75. 75.
    Young JF, Holson JF (1978) Utility of pharmacokinetics in designing toxicological protocols and improving interspecies extrapolation. J Environ Pathol Toxicoloncol 2:169–186Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. Nau
    • 1
  1. 1.Institut für Toxikologie und EmbryonalpharmakologieFreie Universität BerlinBerlin 33Deutschlans

Personalised recommendations